Savant Capital LLC Has $243,000 Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Savant Capital LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 587 shares of the company’s stock after selling 99 shares during the quarter. Savant Capital LLC’s holdings in IDEXX Laboratories were worth $243,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Creative Planning raised its stake in IDEXX Laboratories by 2.6% in the third quarter. Creative Planning now owns 24,436 shares of the company’s stock valued at $12,346,000 after purchasing an additional 614 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of IDEXX Laboratories by 108.5% in the third quarter. Blue Trust Inc. now owns 1,551 shares of the company’s stock worth $756,000 after acquiring an additional 807 shares during the last quarter. Whittier Trust Co. increased its position in IDEXX Laboratories by 10.1% during the 3rd quarter. Whittier Trust Co. now owns 1,673 shares of the company’s stock worth $845,000 after purchasing an additional 153 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in IDEXX Laboratories by 6.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 809 shares of the company’s stock valued at $409,000 after purchasing an additional 48 shares during the last quarter. Finally, Eastern Bank acquired a new stake in IDEXX Laboratories in the third quarter valued at approximately $90,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock worth $6,161,276 in the last 90 days. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Up 1.0 %

IDXX opened at $449.06 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The firm has a market capitalization of $36.77 billion, a P/E ratio of 42.09, a PEG ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The company’s 50-day moving average is $430.82 and its 200 day moving average is $452.56.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IDXX. Morgan Stanley reduced their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Piper Sandler boosted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.